K

I

Invus

Crunchbase
Pitchbook
Crunchbase

Deals on record

17

Common Fundraising Type

Series A

A
Antares Therapeutics

Biotechnology • Precision Medicines

Omega Funds logo
Lightspeed Venture Partners logo
Atlas Venture logo
Willett Advisors logo

Antares Therapeutics is a biotechnology company developing precision medicines for cancer, focusing on small molecule assets and precision oncology.

Series A
$177M
06/17/2025
Article
A
Aive

Video post-production • Automation

Invus logo

Aive is a video post-production automation platform that uses proprietary technology to optimize video content production for various platforms and marketing objectives.

Series A
$13.7M
06/05/2025
Article
R
Rain

Wildfire Containment Technology • Autonomous Aircraft

Spark Growth Ventures logo
QED logo
Prosus logo
Nextalia Ventures logo

Rain is a company that develops autonomous aerial technology for early detection and rapid suppression of wildfires.

Series B
$75M
04/08/2025
Article
B
Bambusa Therapeutics

Biotechnology • Inflammatory

RA Capital Management logo
Redmile Group logo
Janus Henderson Investors logo
Invus logo

Bambusa Therapeutics is a biotechnology company developing transformative treatments for inflammatory and immunological conditions.

Series A
$90M
02/18/2025
Article
L
Leyden Labs

Mucosal Protection • Intranasal Antibody

ClavystBio logo
Qiming Venture Partners logo
Polaris Partners logo
GV logo

Leyden Labs develops non-vaccine intranasal antibody treatments to protect against respiratory viruses like influenza and coronaviruses.

Equity
$70M
01/09/2025
Article
C
Coave Therapeutics

Genetic medicines • ALIGATER™ platform

UI Investissement logo
Turenne Capital logo
Seroba Life Sciences logo
Omnes Capital logo

Coave Therapeutics develops genetic medicines using their ALIGATER™ platform to enhance treatment for CNS, neuromuscular, and eye diseases.

Series A
$33M
01/09/2025
Article
T
Tasca Therapeutics

Biotechnology • Drug Discovery

Cure Ventures logo
Regeneron Ventures logo
Invus Group logo

Tasca Therapeutics is a biotechnology company focused on developing small molecule inhibitors for oncology using a unique drug discovery platform.

Series A
$52M
12/10/2024
Article
Z
Zenflow

Medical device • Minimally invasive

Medical Technology Venture Partners logo
Invus Opportunities logo
F-Prime Capital logo
Cook Medical logo

Zenflow, Inc. develops minimally invasive medical devices for treating urinary obstruction caused by benign prostatic hyperplasia (BPH).

Series C
$24M
11/18/2024
Article
A
Agomab

Biotech • Anti-fibrotic Therapies

Sanofi logo
Invus logo

Agomab Therapeutics is a Belgian biotech company developing novel treatments for fibrosis, with a pipeline of growth factor targeting antibodies and small molecule compounds.

Series D
$88.8M
10/25/2024
Article
V
Vinted

Online marketplace • Second-hand fashion

TPG logo
Moore Strategic Ventures logo
Manhattan Venture Partners logo
Invus Opportunities logo

Vinted is an online marketplace that allows users to buy, sell, and exchange second-hand fashion and electronics.

Equity
$366.6M
10/24/2024
Article
S
Seaport Therapeutics

Neuropsychiatric • Medicines

General Atlantic logo
T. Rowe Price Associates logo
Sofinnova Investments logo
Third Rock Ventures logo

Seaport Therapeutics develops neuropsychiatric medicines using its Glyph technology platform to enhance oral bioavailability and reduce side effects, with a focus on treating depression, anxiety, and other disorders.

Series B
$225M
10/22/2024
Article
C
City Therapeutics

Biopharmaceutical • RNAi

ARCH Venture Partners logo
Regeneron Ventures logo
Rock Springs Capital logo
Slate Path Capital logo

City Therapeutics is a biopharmaceutical company focused on developing RNA interference-based medicines using engineered small interfering RNAs to target a broad range of diseases.

Series A
$135M
10/08/2024
Article
T
Triveni Bio

Biotech • Antibody treatments

Goldman Sachs Alternatives logo
Viking Global Investors logo
OrbiMed logo
Invus logo

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series B
$115M
10/02/2024
Article
E
Engine Biosciences

Precision Oncology • Machine Learning

ClavystBio logo
Polaris Partners logo
SEEDS Capital logo
Invus logo

Engine Biosciences uses machine learning and high-throughput biology to develop precision oncology medicines, and with their recent funding, they plan to advance their biomarker and target discoveries toward the clinic through internal development, collaborations, and partnerships.

Series A
$27M
10/31/2023
Article
T
Triveni Bio

Biotech • Antibody treatments

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Series A
$92M
10/26/2023
Article
P
PayJoy

Fintech • Smartphone-based Finance

Warburg Pincus logo
Union Square Ventures logo
Invus logo
Greylock logo

PayJoy is a San Francisco-based public benefit corporation that provides smartphone-based finance solutions to underserved populations in emerging markets, using its patented mobile security technology to extend credit.

Hybrid C
$360M
09/06/2023
Article